POETIC clinical Trial Ki67 Bookend Breast Cancer Targeted Exome and RNAseq Project

Using RNAseq, we compare the 15% of poorest responders (PRs, n=177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant aromatase inhibitors to good responders (GRs, n=190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories. In the POETIC trial, 4,480 postmenopausal women with primary ER+ BC were randomised 2:1 to receive either treatment with a non-steroidal AI (letrozole or anastrozole) for 2 weeks before and 2 weeks after surgery or to no perisurgical treatment. Only AI-treated patients with HER2- tumors, paired baseline and surgery Ki67 available, and baseline Ki67 immunohistochemistry (IHC) >10% (to minimise imprecision in proportional Ki67 falls) were included for selection. Data is baseline RNAseq and targeted exome DNA sequencing analysis of POETIC Good/Poor Responders to aromatase inhibitors based on change in Ki67.

365 samples
DAC: EGAC00001003274
Technology: Illumina NovaSeq 6000

Access Policy2 Studies Files

Metadata

Request Access

DS DUO:0000007 (version: 2021-02-23)disease specific researchThis data use permission indicates that use is allowed provided it is related to the specified disease.ModifiersMONDO:0007254

The datasets from the POETIC clinical trial are available under restricted access for privacy and legal issues. Access to data or samples can be obtained by submission and approval of a data and sample request form to the POETIC Trial Management Group, which meets several times a year.

The datasets from the POETIC clinical trial are available under restricted access for privacy and legal issues. Access to data or samples can be obtained by submission and approval of a data and sample request form to the POETIC Trial Management Group, which meets several times a year. Please contact Dr. Maggie Cheang or Prof. Judith Bliss and request the data and sample request form. Once the form is filled out and returned, then it will be submitted to the Trial Management Group for approval. The management group meets several times per year.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID	Study Title	Study Type
	Baseline RNAseq analysis of POETIC Good/Poor Responders to aromatase inhibitors based on change in Ki67	RNASeq
	Targeted exome DNA sequencing analysis of POETIC Good/Poor Responders to aromatase inhibitors based on change in Ki67	Exome Sequencing

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID	File Type	Size	Located in